These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7768256)

  • 21. Enzyme induction by moricizine: time course and extent in healthy subjects.
    Benedek IH; Davidson AF; Pieniaszek HJ
    J Clin Pharmacol; 1994 Feb; 34(2):167-75. PubMed ID: 8163717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant weight reduction in obese subjects enhances carbamazepine elimination.
    Caraco Y; Zylber-Katz E; Berry EM; Levy M
    Clin Pharmacol Ther; 1992 May; 51(5):501-6. PubMed ID: 1587063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate).
    Abernethy DR; Greenblatt DJ; Divoll M; Shader RI
    J Pharm Sci; 1982 Aug; 71(8):942-4. PubMed ID: 6811726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects.
    Soto J; Alsar MJ
    J Clin Pharm Ther; 1997 Jun; 22(3):191-5. PubMed ID: 9447474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.
    Anadón A; Martinez-Larrañaga MR; Fernandez MC; Diaz MJ; Bringas P
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2148-51. PubMed ID: 2073104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of zinc supplementation on oxidative drug metabolism in patients with hepatic cirrhosis.
    Barry MG; Macmathuna P; Younger K; Keeling PW; Feely J
    Br J Clin Pharmacol; 1991 Apr; 31(4):488-91. PubMed ID: 2049261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipyrine pharmacokinetics in women receiving conjugated estrogens.
    Scavone JM; Greenblatt DJ; Blyden GT
    J Clin Pharmacol; 1988 May; 28(5):463-6. PubMed ID: 3392245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships among liver and kidney volumes, lean body mass and drug clearance.
    Nawaratne S; Brien JE; Seeman E; Fabiny R; Zalcberg J; Cosolo W; Angus P; Morgan DJ
    Br J Clin Pharmacol; 1998 Nov; 46(5):447-52. PubMed ID: 9833597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.
    Crom WR; Relling MV; Christensen ML; Rivera GK; Evans WE
    Clin Pharmacol Ther; 1991 Aug; 50(2):132-40. PubMed ID: 1868674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibuprofen disposition in obese individuals.
    Abernethy DR; Greenblatt DJ
    Arthritis Rheum; 1985 Oct; 28(10):1117-21. PubMed ID: 4052122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of age, sex and breed on antipyrine disposition in calves.
    Depelchin BO; Bloden S; Michaux C; Ansay M
    Res Vet Sci; 1988 Mar; 44(2):135-9. PubMed ID: 3387662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine.
    Carrum G; Egan JM; Abernethy DR
    Clin Pharmacol Ther; 1986 Aug; 40(2):140-3. PubMed ID: 3731677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipyrin clearance in homozygous beta-thalassemia.
    Rifkind AB; Canale V; New MI
    Clin Pharmacol Ther; 1976 Oct; 20(4):476-83. PubMed ID: 975719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theophylline and antipyrine disposition in smoking and non-smoking epileptic subjects.
    Acheson DW; Uden S; Braganza JM; Brown SW; Houston JB
    Br J Clin Pharmacol; 1987 Dec; 24(6):812-5. PubMed ID: 3440101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of short-term starvation and water deprivation on pharmacokinetics of antipyrine in calves.
    Janus K
    Arch Vet Pol; 1992; 32(3-4):119-25. PubMed ID: 1339567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.
    Cheymol G; Weissenburger J; Poirier JM; Gellee C
    Br J Clin Pharmacol; 1995 Jun; 39(6):684-7. PubMed ID: 7654489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic cage isolation reduces antipyrine clearance in rats.
    Brunner LJ; Dipiro JT; Feldman S
    J Pharm Pharmacol; 1994 Jul; 46(7):581-4. PubMed ID: 7996387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of amiodarone and desethylamiodarone on the pharmacokinetics of antipyrine in the rat.
    Svensson CK; Liu LL; Knowlton PW
    Pharm Res; 1987 Jun; 4(3):251-4. PubMed ID: 3509291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.